St. John’s-based BreatheSuite, whose products help people to use their inhalers properly, has been accepted into the seventh cohort of the prestigious Lazaridis ScaleUp program.

The Lazaridis Institute for the Management of Technology Enterprises, part of the Lazaridis School of Business and Economics at Wilfrid Laurier University in Kitchener, Ont., last week named 11 Canadian companies to the cohort.

BreatheSuite is the only Atlantic Canadian company in the cohort. Since the program began, such Atlantic Canadian companies as QRA Corp. of Halifax, Mysa Smart Thermostats of St. John’s, and Spring Loaded Technology of Dartmouth have attended Lazaridis ScaleUp.

The program aims to help companies accelerate their growth with education and access to a global network of mentors.

Founded in 2018, BreatheSuite has developed software and hardware that aim to correct the improper use of inhalers. Its goal is to improve treatment for the millions of people who suffer from asthma and chronic obstructive pulmonary disease, or COPD, 90 percent of whom are said to use their inhalers improperly.

The company has been active in 2021, hitting a number of milestones. In January, it closed a $1.2 million equity funding round. Then in September, it received 510(K) clearance from the Food and Drug Administration for its device to be sold in the U.S.